Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Colchicine and mortality in patients with coronavirus disease 2019 (COVID-19) pneumonia: A systematic review, meta-analysis, and meta-regression

Eka Noneng Nawangsih a, Yudith Yunia Kusmala b,*, Iis Inayati Rakhmat c, Dewi Ratih Handayani c, Henny Juliastuti c, Arief Wibowo d, Michael Anthonius Lim e, Raymond Pranata d, e

a Department of Microbiology, Faculty of Medicine, Universitas Jenderal Achmad Yani, Cimahi, Indonesia
b Department of Internal Medicine, Faculty of Medicine, Universitas Jenderal Achmad Yani, Cimahi, Indonesia
c Department of Biochemistry, Faculty of Medicine, Universitas Jenderal Achmad Yani, Cimahi, Indonesia
d Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Padjadjaran, Rumah Sakit Umum Pusat Hasan Sadikin, Bandung, Indonesia
e Faculty of Medicine, Universitas Pelita Harapan, Tangerang, Indonesia

ABSTRACT

Objective: This systematic review, with meta-analysis and meta-regression aims to evaluate the effect of colchicine administration on mortality in patients with coronavirus disease 2019 (COVID-19) and factors affecting the association.

Methods: A systematic literature search using the PubMed, Scopus, and Embase databases were performed from inception of databases up until 3 March 2021. We included studies that fulfill all of the following criteria: 1) observational studies or randomized controlled trials (RCTs) that report COVID-19 patients, 2) reporting colchicine use, and 3) mortality within 30 days. There was no restriction on the age, inpatients or outpatients setting, and severity of diseases. The intervention was colchicine administration during treatment for COVID-19. The control was receiving placebo or standard of care. The outcome was mortality and the pooled effect estimate was reported as odds ratio (OR). Random-effects restricted maximum likelihood meta-regression was performed to evaluate factors affecting the pooled effect estimate.

Results: Eight studies comprising of 5530 patients were included in this systematic review and meta-analysis. There were three RCTs and five observational studies. Pooled analysis showed that colchicine was associated with lower mortality in patients with COVID-19 (OR 0.47 [0.31, 0.72], p = 0.001; I²: 30.9, p = 0.181). Meta-regression analysis showed that the association between colchicine and mortality was reduced by increasing age (OR 0.92 [0.85, 1.00], p = 0.05), but not gender (reference: male, p = 0.999), diabetes (p = 0.376), hypertension (p = 0.133), and CAD (p = 0.354).

Conclusion: This meta-analysis indicates that colchicine may reduce mortality in patients with COVID-19. Meta-regression analysis showed that the benefit was reduced as age increases.

PROSPERO: CRD42021240609.
syndrome ARDS, coagulopathy, sepsis, cardiopulmonary collapse, multi-organ dysfunction, and death.[3] Given there is no specific treatment for COVID-19 to date, various combinations of drugs are used to combat the novel coronavirus, including anti-viral medications, anti-inflammatory drugs, and immunomodulatory agents, as seen in pandemics caused by respiratory viruses (SARS, MERS, and H1N1).[4–7] However, these medications are largely ineffective.[8]

Colchicine, an alkaloid derived from the plant family Colchicum autumnale or Gloriosa superba, contains anti-inflammatory properties and therefore may be useful in treating severe and critically-ill COVID-19 patients.[5,9,10] Colchicine may help in mitigating the cytokine release in patients with COVID-19 and thereby improve outcome in these patients. This systematic review, with meta-analysis and meta-regression aims to evaluate the effect of colchicine administration on mortality in patients with COVID-19 and factors affecting the association. We included both randomized controlled trials (RCTs) and observational studies that addresses colchicine administration compared to standard of care or placebo in patients with COVID-19 in terms of mortality.

2. Methods

This is a Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) compliant systematic review and meta-analysis. This study is registered in PROSPERO (CRD42021240609).

2.1. Search strategy and study selection

A systematic literature search using the PubMed, Scopus, and Embase databases were performed using the terms “(COVID-19 OR 2019-nCoV OR SARS-CoV-2) AND (colchicine)” from inception of databases up until 3 March 2021. The full search strategy can be accessed in the Supplementary Table 1. Two authors performed independent screening of title/abstracts. The full-text articles were then assessed for eligibility by evaluating inclusion and exclusion criteria. Discrepancies that arose were resolved by discussion.

2.2. Inclusion and exclusion criteria

We included studies that fulfill all of the following criteria: 1) observational studies or randomized controlled trials that report COVID-19 patients, 2) reporting colchicine use, and 3) mortality within 30 days. There was no restriction on the age, inpatients or outpatients setting, and severity of diseases.

We excluded studies that fulfill one of the following criteria: 1) abstracts, 2) conference papers, 3) letters, and 4) commentaries. We did not impose any language restriction

2.3. Data extraction

Two authors independently extract data from the studies for the first author, study design, colchicine dosing, sample size, age, gender, diabetes, hypertension, coronary artery disease (CAD), the intervention, and the outcome. Discrepancies were resolved by discussion.

2.4. Risk of bias assessment

Two independent authors performed risk of bias assessment of the included studies using the Newcastle-Ottawa Scale (NOS)[11] and Cochrane Risk of Bias Assessment for randomized controlled trials [12]. NOS consists of three domains: 1) selection, 2) comparability, and 3) outcome. Cochrane Risk of Bias Assessment evaluates the possibilities of selection bias, performance bias, detection bias, attrition bias, selective reporting, and other biases. Discrepancies were resolved by discussion. The information derived the risk of bias assessment acts as a note for the included studies but did not modify data synthesis.

2.5. Intervention and outcome

The intervention was colchicine, defined as colchicine administration during treatment for COVID-19. The control was placebo or standard of care. Standard of care was defined as treatment regimen given by the respective study centers. The outcome was mortality, defined as clinically non-survivor/death. The pooled effect estimate was reported as odds ratio (OR).

2.6. Statistical analysis

STATA version 16.0 was used to perform meta-analysis. Der-Simonian Laird random-effects meta-analysis was used to calculate the pooled OR for the mortality from dichotomous values derived from colchicine and control group. Random-effects model was selected regardless of heterogeneity. Pooled effect estimate was considered as statistically significant if the p-value was below ≤0.05 and 95% CI did not cross 1.00. Cochrane’s Q test and I^2 statistic were used to evaluate heterogeneity, in which I^2 values above 50% and p-value below 0.10 indicates substantial heterogeneity. Subgroup analyses were performed for the RCTs and non-RCTs. Sensitivity analysis was performed by removing the study with outpatients setting. Random-effects restricted maximum likelihood (REML) meta-regression analysis was performed to evaluate the effect of baseline characteristics (possible confounders) on the association between colchicine and mortality.

3. Results

3.1. Baseline characteristics

Eight studies comprising of 5530 patients were included in this systematic review and meta-analysis [Fig. 1,4,5,9,13–17] There were three randomized controlled trials and five observational studies. The baseline characteristics and risk of bias assessment based on NOS can be seen in Table 1. Cochrane Risk of Bias assessment can be seen in Fig. 2.

3.2. Colchicine and mortality

Pooled analysis showed that colchicine was associated with lower mortality in patients with COVID-19 (OR 0.47 [0.31, 0.72], p = 0.001; I^2: 30.9%, p = 0.181) [Fig. 3]. Subgroup analysis for observational studies (cohorts) showed mortality reduction (OR 0.48 [0.28, 0.82], I^2: 56.7%), however, pooled RCTs only showed a statistically non-significant trend towards mortality reduction (OR 0.43 [0.17, 1.08], I^2: 0%). Sensitivity analysis by removing Tardif et al. (outpatients setting) showed that the mortality benefit is still statistically significant (OR 0.45 [0.28, 0.74], p = 0.002; I^2: 40.5%, p = 0.121).

3.3. Meta-regression

Meta-regression analysis showed that the benefit of colchicine on mortality was reduced as age increases (OR 0.92 [0.85, 1.00], p = 0.05) [Fig. 4A]. In contrast, gender (reference: male, OR 1.00 [0.97, 1.03], p = 0.999) [Fig. 4B], diabetes (OR 0.99 [0.95, 1.02], p = 0.376) [Fig. 4C], hypertension (OR 0.96 [0.91, 1.01], p = 0.133) [Fig. 4D], and CAD (OR 1.05 [0.94, 1.17], p = 0.354) [Fig. 4E] did not affect the benefit of colchicine on mortality.

3.4. Discussion

This meta-analysis indicates that colchicine may reduce mortality in patients with COVID-19. The largest study (COLCORONA Trial) was done in patients that did not require hospitalization which has low mortality rate. The trial study did not indicate mortality benefit, however, it reduces the rate of hospitalization due to COVID-19 (OR 0.75 [0.57, 0.99]). The rate of pneumonia was lower in the colchicine group.
(2.9% vs. 4.1%, p = 0.02). Thus the benefit of colchicine use is more apparent in hospitalized patients, especially in those with moderate-severe disease, as shown by Brunetti et al., Sandhu et al., and Scarsi et al. studies.[9,14,15] Meta-regression analysis showed that the benefit was reduced as age increases.

We included both placebo or standard of care as a control group because of the lack of studies, while this might pose as a source of bias due to different methodological quality in double-blinded studies compared to open label studies, it is unlikely that administration of placebo on top of standard of care will cause considerable difference in terms of mortality. Nevertheless, varying COVID-19 treatment protocol among institutions and countries may cause heterogeneity. Subgroup analysis showed that the effect is more pronounced in the observational studies. The RCTs subgroup has 0% heterogeneity and trend towards lower mortality but was not statistically significant. The RCTs comprised of two inpatients and one outpatients study, the two inpatients study have small sample size and event rates that may not provide adequate power to detect significance. This is in contrast with the observational studies, in which the incidence of mortality was higher, and the sample size was larger. However, observational studies were prone to biases, although NOS indicates that the studies have low-moderate risk of bias, it is not as robust as the RCTs. The RCTs included in the pooled analysis pose no serious risk of bias except for one study which was open-label. There was serious risk of imprecision in the RCTs but not observational studies. Further RCTs in the hospitalized patients with larger samples are required.

Colchicine, an alkaloid derived from the plant family Colchicum autumnale or Gloriosa superba, contains both anti-viral and anti-inflammatory properties and therefore may be useful in treating severe and critically-ill COVID-19 patients.[5,9,10] Colchicine binds with tubulin to form complexes which disrupts neutrophil chemotaxis, adhesion, and mobilization, interferes superoxide generation, inflammasome activation, destabilization, and degradation, as well as TNF inhibition.[9,13,14,18] One of the main mechanism is the inhibition of Nod-like receptor protein 3 (NLRP-3), an inflammasome associated with the severe COVID-19 infection and poor clinical outcome, which consequently leads to decreased in IL-1β and IL-18 concentrations.[5,15] Initially, colchicine prevents purinergic type 2 (P2X7) receptor activation and ASC polymerization, thereby hindering interaction between pyrin-like domains, and then suppressing mitochondrial transport and subsequent approximation of apoptosis-associated speck like protein containing a caspase recruitment domain (ASC) to NLRP3.[17]

Within the host cell, intracellular transport of viral particles assisted by microtubules and associated proteins is also hindered by colchicine. Viral load reduction results in a decrease in the secretion of pro-inflammatory cytokines, which contributes to soothe uncontrolled cytokine storm.[9] Furthermore, colchicine has a cardioprotective effect because it improves endothelial function and enhances the concentration of peripheral white blood cells.[13,18] This can be useful considering that cardiovascular complications is a possibility for patients with
Table 1  
Baseline Characteristics of the Included Studies.

| Authors          | Design       | Samples          | Severity of COVID-19 (%) | Colchicine Dose (Initial) | Maintenance Dose | Control | Duration of Treatment | Age (years) | Male (%) | Diabetes (%) | Hypertension (%) | CAD (%) | Follow-up (days) | NOS |
|------------------|--------------|------------------|---------------------------|---------------------------|------------------|---------|-----------------------|--------------|----------|---------------|------------------|---------|-----------------|-----|
| Brunetti 2020    | PSM Cohort   | 66 (33 vs 33)    | Severe: 100%             | 1.2 mg (73%)              | 0.6 mg twice daily | SOC     | Unclear               | 63           | 65       | 79            | 49               | 9       | 28              | 8   |
| Deftereos 2020   | RCT          | 105 (55 vs 50)   | Unclear                  | 1.5 mg + 0.5 mg           | 0.5 mg twice daily | SOC     | Until discharge or 21 days | 58           | 58       | 20            | 45               | 13      | 21              | See RoB (Fig. 2) |
| Lopes 2021       | RCT          | 75 (37 vs 38)    | Percentage unknown, Enrol moderate-severe COVID-19 | 1.0 mg                  | 0.5 mg thrice daily | Placebo | 5 days                | 55           | 46       | 39            | Unclear          | Unclear | 26              | See RoB (Fig. 2) |
| Mahale 2020      | RC           | 134 (39 vs 95)   | Mild ARDS: 31.3°          | No loading               | 0.5 mg per day    | SOC     | Unclear               | 56           | 68       | 44            | 46               | 19      | Unclear         | 7   |
|                  |              |                  | Severe ARDS: 13.4°        |                          |                  |         |                       |               |          |               |                  |         |                 |     |
| Pinzon 2021      | CS           | 301 (145 vs 156) | Normal: 14.9°             | No loading               | 0.5 mg twice daily | SOC     | 7-14 days             | 57           | 59       | 24            | 46               | 6       | Until Discharge | 7   |
| Sandhu 2020      | PC           | 112 (34 vs 78)   | Percentage unknown, Enrol moderate-severe COVID-19 | No loading               | 0.6 mg twice daily | SOC     | 12 days               | 67           | 55       | 46            | 66               | 7       | Until Discharge | 7   |
| Scarsi 2020      | PC           | 262 (122 vs 140) | Severe: 100               | No loading               | 1.0 mg per day    | SOC     | Unclear               | 64           | 12       | 12            | Unclear          | Unclear | 21              | 8   |
| Tardif 2021      | RCT          | 4159 (2075 vs 2084) | Unclear, possibly there is no severe COVID-19 | No loading               | 0.5 mg twice daily | Placebo | 30 days               | 55           | 46       | 20            | 36               | 3       | 30              | See RoB (Fig. 2) |

CAD: Coronary Artery Disease, CS: Cross-sectional, PC: Prospective Cohort, PSM: Propensity-Score Matched; RC: Retrospective Cohort, RCT: Randomized Controlled Trial, RoB: Risk of Bias, NOS: Newcastle-Ottawa Scale.

* Based on P/F ratio.
Patients with advanced age, obesity, frailty, and pre-existing non-communicable conditions, are associated with an increased risk of experiencing cytokine storm and developing severe COVID-19. [21,22] These comorbidities generally cause a low-grade, chronic, systemic pro-inflammatory state. [23–25] Colchicine has been used in many hyper-inflammatory conditions, including gout arthropathy, acute pericarditis, and periodic febrile illnesses. [14,18] In COVID-19 cases, the use of colchicine was associated with a reduction in the concentration of inflammatory parameters, including CRP, D-dimer, ferritin and IL-6. [5,9,13–15] Therefore, colchicine can be a promising option for battling hyperinflammation of COVID-19, given that this medication is widely available at low cost and has a well-known safety profile with only mild side effects. [14,15,18] The most commonly observed adverse events were gastro-intestinal symptoms, such as diarrhea, vomiting, and abdominal pain. [13,14,16]

There are several limitations of this systematic review and meta-analysis. First is the small number of studies and the variety of dose regimens of colchicine, ranging from 0.5 to 1.5 mg per day. Secondly, there might be small-study effects because large studies are weighted in close approximation with the small study. Thirdly, there are studies with small number of events which might be underpowered.

There are a number of deviations from the protocol. First, subgroup analyses were performed for RCTs and observational studies, since the authors did not know whether subgroup analyses were possible considering the number of studies, these were not pre-specified. Secondly, we did not perform funnel-plot analysis or Egger’s test due to because there were less than ten studies. Thirdly, to provide a more specific and clear definition, we defined the control group into placebo or standard of care. Finally, we one of three RCTs was outpatient setting, at first the authors only wanted to evaluate hospitalized patients; however, COLCORONA (Tardif et al.) is an important trial with a large sample size. Thus, the authors decided to include the study and added a

| Study                        | Colchicine | Control | Odds Ratio with 95% CI | Weight (%) |
|------------------------------|------------|---------|------------------------|------------|
| **Observational Studies (Cohorts)** |            |         |                        |            |
| Brunetti 2020                | Yes 3      | No 30   | Yes 11                 | No 22      | 0.20 [0.05, 0.80] | 7.63 |
| Mahale 2020                  | Yes 11     | No 28   | Yes 25                 | No 70      | 1.10 [0.48, 2.53] | 16.19 |
| Pinzon 2021                  | Yes 14     | No 131  | Yes 23                 | No 133     | 0.62 [0.30, 1.25] | 19.67 |
| Sandhu 2020                  | Yes 16     | No 18   | Yes 63                 | No 15      | 0.21 [0.09, 0.51] | 15.15 |
| Scarsi 2020                  | Yes 20     | No 102  | Yes 72                 | No 190     | 0.52 [0.30, 0.90] | 25.10 |
| Heterogeneity: $\chi^2 = 0.21$, $I^2 = 56.27\%$, $H^2 = 2.29$ | | | | | 0.48 [0.28, 0.82] |
| Test of $\theta = 0$: $Q(4) = 9.15$, $p = 0.06$ | | | | | |

| **Randomized Controlled Trials** |            |         |                        |            |
| Deftereos (GRECCO-19) 2020     | Yes 1      | No 54   | Yes 4                  | No 46      | 0.21 [0.02, 1.97] | 3.33 |
| Lopes 2020                    | Yes 0      | No 36   | Yes 2                  | No 34      | 0.19 [0.01, 4.08] | 1.81 |
| Tardif (COLCORONA) 2021       | Yes 5      | No 2,070| Yes 9                 | No 2,075   | 0.56 [0.19, 1.66] | 11.11 |
| Heterogeneity: $\chi^2 = 0.00$, $I^2 = 0.00\%$, $H^2 = 1.00$ | | | | | 0.43 [0.17, 1.08] |
| Test of $\theta = 0$: $Q(2) = 0.87$, $p = 0.65$ | | | | | |

**Overall**

Heterogeneity: $\chi^2 = 0.11$, $I^2 = 30.92\%$, $H^2 = 1.45$

Test of $\theta = 0$: $Q(7) = 10.13$, $p = 0.18$

Test of group differences: $Q_1(1) = 0.04$, $p = 0.84$

Random-effects DerSimonian-Laird model

1/64 1/16 1/4 1 4

Fig. 3. Colchicine and Mortality in COVID-19.

---

**Fig. 2. Summary of Cochrane Risk of Bias Assessment.**
sensitivity analysis instead, both pooled effect estimates with or without COLCORONA inclusion demonstrate statistical significance.

In conclusion, this meta-analysis indicates that colchicine may reduce mortality in patients with COVID-19. Meta-regression analysis showed that the benefit was reduced as age increases.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

None.

Funding

None.
References

[1] I. Huang, R. Pranata, M.A. Lim, A. Oehadian, B. Alisjahbana, C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis, Ther. Adv. Respir. Dis. 14 (2020), https://doi.org/10.1177/1753483420958873.

[2] E. Yonan, I. Alwi, R. Pranata, I. Huang, M.A. Lim, M. Yamin, S.A. Nasution, S. Setiati, S.S. Virani, Elevated interleukin levels are associated with higher severity and mortality in COVID-19: A systematic review, meta-analysis, and meta-regression, Diabetes Metab. Syndr. Clin. Res. Rev. 14 (2020) 2219–2230, https://doi.org/10.1016/j.dsx.2020.11.011.

[3] M.A. Lim, R. Pranata, I. Huang, E. Yonan, A.Y. Soeroet, R. Supriyadi, Multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: systematic review and meta-analysis, Can. J. Kidney Heal. Dis. 7 (2020), https://doi.org/10.1177/2054380820958873.

[4] B. Purandare, B. Patil, V. Patil, M. Madan, S. Deshpande, P. Chavan, E. Vaidya, K. Kulkarni, R. Bhalerao, A. Pathak, A. Patil, S. Khadke, S. Kulkarni, J. Ganesh, M. Turakhia, S. Joshi, A. Pratap, R. Pranata, M.A. Lim, E. Yonan, R. Supriyadi, Multiorgan failure with emphasis on acute kidney injury and severity of COVID-19: A systematic review, meta-analysis, and meta-regression, Diabetes Metab. Syndr. Clin. Res. Rev. 14 (2020) 2219–2230, https://doi.org/10.1016/j.dsx.2020.11.011.

[5] M.A. Lim, R. Pranata, M. Shahane, A. Prayag, S. Gugale, S. Bhor, A retrospective observational study of hypoxic COVID-19 patients treated with immunomodulatory drugs in a tertiary care hospital, Indian J. Crit. Care Med. 24 (2020) 1020–1027, https://doi.org/10.5005/jp-journals-10071-23599.

[6] M. Alejandro Pinzon, C. Medellin Doris Cardona Arango, J. Felipe Betancur, C. Arias Arias, B. Javier Muñoz, J. Felipe Llano Clínica Medellin Pablo Montoya, Clinical outcome of COVID-19 patients with pneumonia treated with corticosteroids and colchicine in colombia, Res. Sq. (2020) 1.

[7] D.S. Hui, N. Lee, P.K. Chan, J.H. Beigel, The role of adjuvant immunomodulatory agents for treatment of severe influenza, Antiviral Res. 150 (2018) 202–216, https://doi.org/10.1016/j.antiviral.2018.01.002.

[8] W. Zhang, Y. Zhao, F. Wang, Q. Wang, T. Li, Z. Liu, J. Wang, Y. Qin, X. Zhang, X. Yan, X. Zeng, S. Zhang, The use of anti-inflammatory drugs in the treatment of COVID-19 patients with severe coronavirus disease 2019 (COVID-19): The experience of clinical immunologists from China, Clin. Immunol. 214 (2020), https://doi.org/10.1016/j.cellimm.2020.108393.

[9] R.A.C. Siemieniuk, J.J. Bartoszko, L. Ge, D. Zeraatkar, A. Izcovich, H. Pardo-Junior, R.D.R. Oliveira, Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial, RMD Open. 7 (2021), e001455, https://doi.org/10.1136/rmdopen-2020-001455.

[10] T. Sandhu, A. Tieng, S. Chilimuri, J. Peterson, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, Ottawa, Ottawa Hosp. Res, Inst, 2000 http://www.ofri.ca/programs/c clinical.epidemiology/ tool.

[11] J.P.T. Higgins, D.G. Altman, P.C. Gastecke, P. Juni, D. Moher, A.D. Oxman, J. Savovic, K.F. Schulz, L. Weeks, J.A.C. Sterne, The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials, BMJ. 343 (2011), https://doi.org/10.1136/bmj.d5926.

[12] M.I. Lopes, L.P. Bonjorno, M.C. Giannini, N.B. Amaral, P.I. Menezes, S.M. Dib, S. L. Gigante, M.N. Benatti, U.C. Rezek, L.L. Emrich-Filho, B.A.A. Sousa, S.C. L. Almeida, R. Luppino Assad, F.P. Veras, A. Schneider, T.S. Rodrigues, L.O. S. Leitão, L.C. Junca, J.C. Alves-Filho, T.M. Cunha, E. Arruda, C.H. Miranda, A. Pazin-Filho, M. Auxiliadora-Martins, M.C. Borges, B.A.L. Foncea, V.R. Bollela, C.M. Del-Ben, F.Q. Cunha, D.S. Zamboni, R.C. Santana, F.C. Vilar, P. Louzada-Junior, R.D.R. Oliveira, Beneficial effects of colchicine for moderate to severe COVID-19: A randomised, double-blinded, placebo-controlled clinical trial, RMD Open. 7 (2021), e001455, https://doi.org/10.1136/rmdopen-2020-001455.